Literature DB >> 7738649

Detecting recurrent or residual lung cancer with FDG-PET.

T Inoue1, E E Kim, R Komaki, F C Wong, P Bassa, W H Wong, D J Yang, K Endo, D A Podoloff.   

Abstract

UNLABELLED: We investigated the diagnostic accuracy of FDG-PET in the detection of recurrent lung cancer.
METHODS: Thirty-nine lesions in 38 patients with clinically suspected recurrent or residual lung cancer were studied with PET. All PET images were visually interpreted in conjunction with thoracic CT or MRI. Semiquantitative analysis using standardized uptake values (SUVs) was also performed in 25 lesions. FDG-PET diagnoses were correlated with pathological diagnoses and clinical outcome.
RESULTS: The sensitivity and specificity of FDG-PET for detecting recurrent tumors were 100% (26/26) and 61.5% (8/13), respectively. The difference in mean SUV between recurrent tumors and noncancerous lesions was statistically significant [11.2 +/- 5.7 (n = 16) vs. 3.5 +/- 1.8 (n = 9), p < 0.0001]. False-positive results showed relatively lower SUVs than true-positives and also demonstrated increased uptake in a curvilinear rather than nodular shape.
CONCLUSION: FDG-PET is useful for detecting recurrent lung cancer after treatment. False-positive diagnoses might be reduced by analysis of uptake shape and serial changes in SUV, but further study is needed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7738649

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  21 in total

1.  FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses.

Authors:  J Aoki; H Watanabe; T Shinozaki; K Takagishi; M Tokunaga; Y Koyama; N Sato; K Endo
Journal:  Skeletal Radiol       Date:  2003-01-24       Impact factor: 2.199

2.  99mTc-MIBI scintigraphy for early detection of locally recurrent non-small cell lung cancer treated with definitive radiation therapy.

Authors:  Masaya Furuta; Miwako Nozaki; Miho Kawashima; Mamoru Iimuro; Yoshinori Kitazumi; Aya Okayama; Satoshi Natsui; Yoshio Hamashima; Koushuu Nagao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

3.  Requirements for clinical PET: comparisons within Europe.

Authors:  Michael Bedford; Michael N Maisey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

4.  Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.

Authors:  Dirk Hellwig; Andreas Gröschel; Thomas P Graeter; Anne P Hellwig; Ursula Nestle; Hans-Joachim Schäfers; Gerhard W Sybrecht; Carl-Martin Kirsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-09       Impact factor: 9.236

5.  Influx rate of 18F-fluoroaminosuberic acid reflects cystine/glutamate antiporter expression in tumour xenografts.

Authors:  Kathinka E Pitman; Santosh R Alluri; Alexander Kristian; Eva-Katrine Aarnes; Heidi Lyng; Patrick J Riss; Eirik Malinen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-01       Impact factor: 9.236

Review 6.  18F-fluorodeoxyglucose PET scans in lung cancer.

Authors:  J M Hughes
Journal:  Thorax       Date:  1996-08       Impact factor: 9.139

Review 7.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

Review 8.  Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients.

Authors:  L G Strauss
Journal:  Eur J Nucl Med       Date:  1996-10

Review 9.  Current role of positron emission tomography in thoracic oncology.

Authors:  V J Lowe; K S Naunheim
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

10.  Usefulness of fluoro-2-deoxyglucose positron emission tomography for investigating unexplained rising carcinoembryonic antigen levels that occur during the postoperative surveillance of lung cancer patients.

Authors:  Kazutoshi Isobe; Yoshinobu Hata; Yujiro Takai; Kazutoshi Shibuya; Keigo Takagi; Sakae Homma
Journal:  Int J Clin Oncol       Date:  2009-12-05       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.